688166.SHG BrightGene Bio Medical Technology C

Healthcare Biotechnology Shanghai Stock Exchange
31.68 CNY
Close of Nov 5, 2026
28.50 72.88
Market cap
CNY 13.8B
P/E
132.0x
P/B
4.15x
ROE
4.2%
Dividend yield
0.85%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 688166.SHG undervalued?

Graham number

The Graham number of BrightGene Bio Medical Technology C cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BrightGene Bio Medical Technology C fundamental analysis

No fundamental analysis for BrightGene Bio Medical Technology C yet.

BrightGene Bio Medical Technology C stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BrightGene Bio Medical Technology C

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; active pharmaceutical ingredients and intermediates; and ve…

Full company profile